IMIDomics Inc.

IMIDomics Inc. is a biotechnology startup with the slogan "Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases (IMIDs)." Founded in 2015, the company is headquartered in the United States and operates within the Biotechnology and Health Care industries.

IMIDomics focuses on patient-centric drug discovery for IMIDs, aiming to discover new and impactful IMID drugs by carefully selecting patients and stratifying populations to identify those most likely to respond. The company boasts a unique Clinical Discovery EngineTM, which integrates and analyzes proprietary clinical, epidemiological, and patient-derived biomolecular datasets generated in partnership with the Vall d’Hebron Institute of Research to establish a deeper understanding of IMID diseases.

IMIDomics has identified previously unrecognized targets, six of which have been selected for development. The company recently secured a Corporate Round investment on 04 March 2024, with Union Chimique Belge becoming the latest investor, bolstering their efforts to enhance the probability of successful IMID drug discovery and development for those in need.